MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/annrheumdis-2020-217344

Медицинская библиотека · Annals of the rheumatic diseases · 2020

EULAR definition of difficult-to-treat rheumatoid arthritis.

Nagy György, Roodenrijs Nadia Mt, Welsing Paco Mj, Kedves Melinda, Hamar Attila, van der Goes Marlies C, Kent Alison, Bakkers Margot, Blaas Etienne, Senolt Ladislav, Szekanecz Zoltan, Choy Ernest, Dougados Maxime, Jacobs Johannes Wg, Geenen Rinie, Bijlsma Hans Wj, Zink Angela, Aletaha Daniel, Schoneveld Leonard, van Riel Piet, Gutermann Loriane, Prior Yeliz, Nikiphorou Elena, Ferraccioli Gianfranco, Schett Georg, Hyrich Kimme L, Mueller-Ladner Ulf, Buch Maya H, McInnes Iain B, van der Heijde Désirée, van Laar Jacob M

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking.

OBJECTIVE

The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step.

METHODS

The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting).

RESULTS

The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient.

CONCLUSIONS

The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.

Для цитирования: Nagy György, Roodenrijs Nadia Mt, Welsing Paco Mj, Kedves Melinda, Hamar Attila, van der Goes Marlies C, Kent Alison, Bakkers Margot, Blaas Etienne, Senolt Ladislav, Szekanecz Zoltan, Choy Ernest, Dougados Maxime, Jacobs Johannes Wg, Geenen Rinie, Bijlsma Hans Wj, Zink Angela, Aletaha Daniel, Schoneveld Leonard, van Riel Piet, Gutermann Loriane, Prior Yeliz, Nikiphorou Elena, Ferraccioli Gianfranco, Schett Georg, Hyrich Kimme L, Mueller-Ladner Ulf, Buch Maya H, McInnes Iain B, van der Heijde Désirée, van Laar Jacob M. EULAR definition of difficult-to-treat rheumatoid arthritis.. Annals of the rheumatic diseases. 2020. DOI: 10.1136/annrheumdis-2020-217344.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.